Inhaled cannabis appears to provide short-term relief from chronic neuropathic pain for 1 in 5 to 6 patients treated.
Our novel Bayesian hierarchical model allowed the synthesis of all available patient data from 5 RCTs with disparate design and outcome reporting.
Pragmatic long-term studies are needed to confirm the safety and effectiveness of inhaled cannabis for chronic neuropathic pain in the community.